Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

PROVIDENCE, R.I. (AP) Kino Lilly Jr. had 16 points in Brown's 98-57 victory against Johnson & Wales on Sunday. Lilly also added eight assists for the Bears (8-5). N'famara Dabo scored 12 points ...

Kennedy Jr. oversee the nation’s health care system ... according to Chicago-based stock researcher Zack’s. Eli Lilly said it expected full-year adjusted earnings of $13.02 to $13.52 per ...

Eli Lilly (NYSE:LLY) shares continued to soar this ... Retatrutide product,” wrote Seeking Alpha Investing Group Leader JR Research. The analyst pointed out that compared to CagriSema’s ...